|1.||Jalan, Rajiv: 7 articles (11/2014 - 07/2009)|
|2.||Crépin, Michel: 4 articles (03/2008 - 04/2002)|
|3.||Cardona, Silvia T: 3 articles (11/2014 - 11/2008)|
|4.||Liu, Chung-Hsien: 3 articles (01/2009 - 12/2002)|
|5.||Chan, Hsu-Chin: 3 articles (01/2009 - 12/2002)|
|6.||Kuo, Sheng-Chu: 3 articles (01/2009 - 12/2002)|
|7.||Kraemer, M: 3 articles (01/2004 - 05/2001)|
|8.||Jozefonvicz, J: 3 articles (01/2004 - 09/2001)|
|9.||Sidell, N: 3 articles (07/2003 - 05/2001)|
|10.||Kristiansen, Rune Gangsøy: 2 articles (11/2014 - 07/2009)|
06/01/2002 - "Phenylbutyrate (4-phenylbutyric acid; PB) and its metabolite, phenylacetate, are effective anti-neoplastic agents in tissue culture and have shown promise in clinical trials for a variety of neoplasms. "
01/01/2009 - "In this study, the potential usage of synthetic phenylacetate derivatives, 4-fluoro-N-butylphenylacetamides (H6) was investigated in human cervical cancer cells. "
02/01/2004 - "Phenylbutyrate (PB) and phenylacetate (PA) have antiproliferative and differentiation-inducing effects in malignant tumors, and had been evaluated in Phase I/II clinical trials. "
11/01/2009 - "An aromatic fatty acid, phenylacetate (PA), has been shown to have cytostatic, antitumor and cell differentiation-inducing effects on various kinds of tumors. "
01/01/2009 - "Phenylacetate induced tumor cytostasis and differentiation. "
09/01/2002 - "Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy."
04/01/2004 - "A pharmacokinetic study of sodium phenylacetate/sodium benzoate (NAPA/NABZ) was performed in two groups of normal healthy volunteers, following the dosing regimen used to treat hyperammonemia. "
01/01/2013 - "Interorgan metabolism of ornithine phenylacetate (OP)--a novel strategy for treatment of hyperammonemia."
01/01/2012 - "Ornithine phenylacetate (OP) reduces hyperammonemia and brain water in cirrhotic animals. "
09/01/2002 - "Sodium phenylacetate powder should be an essential drug for the treatment of hyperammonemia caused by an inborn error of the urea cycle."
12/01/2013 - "Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio."
01/01/2013 - "Combined administration of ornithine and phenylacetate (OP) is proposed as a novel treatment of hyperammonemia and hepatic encephalopathy. "
01/01/2007 - "L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy."
01/01/2012 - "Ornithine phenylacetate (OP) is a new drug that has been proposed for the treatment of hepatic encephalopathy (HE) because it decreases plasma ammonia. "
|4.||Osteosarcoma (Osteogenic Sarcoma)
10/01/2004 - "In this study, we investigated whether phenylacetate is effective against two osteosarcoma cell lines (HOS and U-2 OS) in vitro. "
10/01/2004 - "These findings support the idea that phenylacetate may be an effective chemotherapeutic agent to be employed in the future against osteosarcoma, because phenylacetate acts to inhibit the growth of osteosarcoma cells through cell cycle arrest and apoptosis."
10/01/2004 - "Phenylacetate was found to inhibit the growth of osteosarcoma cells, induce cell cycle arrest in the G1 phase, and induce apoptosis. "
10/01/2004 - "However, the exact mechanism as to how phenylacetate induces cell growth arrest remains unclear and very little is known about its effects on human osteosarcoma cells. "
10/01/2004 - "Phenylacetate induces growth inhibition and apoptosis of human osteosarcoma cells."
01/01/1983 - "In experimental phenylketonuria, induced in the rat by exposure to phenylacetate during the first 21 days of life, there was a significant reduction of boutons, a decrease of an average of 25% in the whole cerebellar molecular layer. "
01/01/1983 - "Results are interpreted to show a deficit of synapses per neuron, probably due to a decrease in synaptic formation in phenylacetate-induced phenylketonuria. "
01/01/1983 - "Experimental phenylketonuria: effect of phenylacetate intoxication on number of synapses in the cerebellar cortex of the rat."
01/01/1981 - "Results of this investigation clearly define the harmful effects of phenylacetate on developing neurons and are compatible with the clinical observation that brain damage in phenylketonuria occurs mainly during the first few years of life, the critical period of neuronal development."
01/01/1981 - "A comparison was made of cerebellar dendritic development in the normal rat and in a new model of phenylketonuria, the phenylacetate-treated suckling rat. "
|3.||Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)
|1.||Renal Dialysis (Hemodialysis)
|2.||Drug Therapy (Chemotherapy)
|4.||Minor Surgical Procedures (Minor Surgery)